Injectable Oncology Medical Program Update

Effective October 1, 2022, Herceptin Hylecta and Rituxan Hycela products will now be added to Blue Cross and Blue Shield of North Carolina’s (Blue Cross NC) ’s Preferred Injectable Oncology Program policy as non-preferred products.

These products will no longer require submission through the AIM Provider Portal in Blue e. Requests for these products for an applicable commercial member will need to be submitted through CoverMyMeds instead of through the AIM portal starting 10/1/2022.

AIM will continue to conduct clinical reviews for all other drugs in the AIM medical oncology program.

For more information, please refer to the medical policy (PDF) or refer to Getting Your Patient's Prescriptions Covered.

What you should know

• This change applies to all commercial members with the AIM oncology program through Blue Cross NC.
• This follows a similar process to how our other medical drugs are reviewed at Blue Cross NC.
• We do not anticipate any member disruption.